Comparative Pharmacology
Head-to-head clinical analysis: GANCICLOVIR SODIUM versus VEKLURY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANCICLOVIR SODIUM versus VEKLURY.
GANCICLOVIR SODIUM vs VEKLURY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ganciclovir is a synthetic guanine derivative that inhibits viral DNA synthesis. It is phosphorylated to ganciclovir triphosphate by viral thymidine kinase (CMV UL97 gene product) and cellular kinases. Ganciclovir triphosphate competitively inhibits viral DNA polymerase (CMV UL54 gene product) and incorporates into viral DNA, causing chain termination.
Remdesivir is a nucleotide analog prodrug that, after intracellular metabolism, incorporates into nascent viral RNA chains causing synthesis termination and inhibition of RNA-dependent RNA polymerase (RdRp). It targets the SARS-CoV-2 RdRp with selectivity over human RNA polymerases.
5 mg/kg IV every 12 hours for 14-21 days for induction; 5 mg/kg IV once daily or 6 mg/kg IV once daily 5 days per week for maintenance. Oral ganciclovir not available as sodium salt.
200 mg IV on Day 1, then 100 mg IV once daily for 5 to 10 days.
None Documented
None Documented
Terminal half-life: 2.5-3.6 hours in normal renal function; prolonged in renal impairment (up to 30 hours in severe cases). Dosage adjustment required for CrCl <80 mL/min.
Remdesivir: ~1 hour (parent); GS-441524: ~27 hours (terminal). Context: GS-441524 accumulation may occur with daily dosing.
Renal: >90% unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <1%.
Renal: 10% unchanged remdesivir; 49% as metabolite GS-441524; 18% as other metabolites. Fecal: 47.5% as metabolites. Biliary: minor.
Category D/X
Category C
Antiviral
Antiviral